Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
- DOI
- 10.1016/j.msard.2019.01.019
- Published
- 2019-01-06
- Container
- Mult Scler Relat Disord
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.msard.2019.01.019,
title = {Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).},
author = {Vukusic S and Brassat D and de Seze J and Izquierdo G and Lysandropoulos A and Moll W and Vanopdenbosch L and Arque MJ and Kertous M and Rufi P and Oreja-Guevara C.},
year = {2019},
journal = {Mult Scler Relat Disord},
doi = {10.1016/j.msard.2019.01.019},
url = {https://doi.org/10.1016/j.msard.2019.01.019}
}RIS
TY - JOUR TI - Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD). AU - Vukusic S AU - Brassat D AU - de Seze J AU - Izquierdo G AU - Lysandropoulos A AU - Moll W AU - Vanopdenbosch L AU - Arque MJ AU - Kertous M AU - Rufi P AU - Oreja-Guevara C. PY - 2019 JO - Mult Scler Relat Disord DO - 10.1016/j.msard.2019.01.019 UR - https://doi.org/10.1016/j.msard.2019.01.019 ER -
APA
S, V., D, B., J, D. S., G, I., A, L., W, M., L, V., MJ, A., M, K., P, R., & C., O. (2019). Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).. Mult Scler Relat Disord. https://doi.org/10.1016/j.msard.2019.01.019
Source records
- europe-pmc · retrieved 2026-09-27T01:23:44.326Z
- hal · retrieved 2026-09-27T01:23:44.343Z